Navigation Links
Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
Date:11/19/2012

WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ -- In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red Cross in an effort to help provide relief to the many areas damaged by Hurricane Sandy.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

"The devastation caused by Hurricane Sandy has affected so many people throughout the East Coast, including many of our employees and their relatives, friends and neighbors," said Lonnel Coats, President and CEO of Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd. "We hope these donations will support efforts to help ease the burden and suffering for those whose lives have been disrupted in very challenging ways."  

Eisai USA Foundation Inc.

The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's commitment to be a responsible corporate citizen and contribute to the good of the society in which it does business. The Foundation focuses its charitable giving in four areas: health-related initiatives for patients and caregivers, disaster relief efforts, innovation in medical and pharmaceutical sciences, and community activities in the areas where Eisai's U.S. employees live and work.  

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
2. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
3. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
4. The Michael J. Fox Foundation Announces Fourth Quarter Participants in Partnering Program Between Awardees and Industry
5. Annai Systems And ThoughtWorks Develop Evidence Engine For The Clearity Foundation To Individualize Options For Treatment Of Ovarian Cancer
6. National Patient Advocate Foundation Urges Ohio Legislature to Support Oral Chemotherapy Legislation
7. New Jersey Health Foundation Commits $2 Million to Fund Grants
8. Henry Schein, Its Supplier Partners and The Henry Schein Cares Foundation Commit to Donate More Than $1 Million to Relief Efforts for Hurricane Sandy
9. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
10. American Board of Radiology Foundation receives grant from Varian Medical Systems for national brachytherapy registry
11. Oncology Systems Limited UK Renews Research and Collaboration Agreement with University Hospital Birmingham NHS Foundation Trust (UHB) - Radiotherapy Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- CANTEL MEDICAL CORP. (NYSE: CMD ) reported ... diluted share, on a 22.1% increase in sales to a ... This compares with net income of $14,254,000, or $0.34 per ... ended October 31, 2015. Non-GAAP net income ... to $21,323,000, or $0.51 per diluted share, compared with non-GAAP ...
(Date:12/8/2016)... 8, 2016   Mederi Therapeutics Inc . has announced regulatory approval by CFDA ... treatment for chronic gastroesophageal reflux disease (GERD). Continue ... ... the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at ... , "We are very pleased that Mederi ...
(Date:12/8/2016)... , and SAN DIEGO , Dec. ... services and solutions with cutting edge next-generation sequencing and bioinformatics ... biotechnology company; and the Genome Institute of Singapore ... – a new joint venture between Novogene and AITbiotech – ... Biopolis, Singapore .   The ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial consulting services to residential and commercial clients in the northern Alabama and ... for Nobis Works. , Since 1977, Nobis Works has built a network of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... OC87 ... with a schizophrenic mother in a unique, personal perspective through animation. , ... trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, lived ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
Breaking Medicine News(10 mins):